Navigation Links
Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
Date:9/13/2009

SAN ANTONIO and SAN CARLOS, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented clinical study data today demonstrating that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactions. NKTR-118, an oral peripherally-acting opioid antagonist, is in clinical development for the treatment of opioid-induced constipation. These findings were presented today at the 38th Annual American College of Clinical Pharmacology (ACCP) Meeting in San Antonio, Texas.

Oral NKTR-118 combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's proprietary advanced polymer conjugate technology increases the bioavailability and half-life of naloxol, enabling NKTR-118 to act selectively in the periphery while preserving centrally-mediated opioid analgesic clinical benefits.

"The data reported today, in combination with our strong Phase 2 clinical results, support advancing the oral tablet formulation of NKTR-118 into pivotal Phase 3 studies. NKTR-118 is an excellent example of how our novel advanced polymer conjugate platform improves oral bioavailability and enables preferential distribution of a drug within the body," said Lorianne Masuoka, M.D., Chief Medical Officer of Nektar. "By significantly improving the pharmacological activity of small molecule drugs, we are building an impressive portfolio of innovative treatments for diseases with high unmet needs."

A human pharmacokinetic study conducted in 20 healthy subjects demonstrated the comparative bioavailability of NKTR-118 in tablets and solution, confirming the drug's rapid absorption prof
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
(Date:9/16/2014)... RICHMOND, Va. , Sept. 16, 2014 /PRNewswire-USNewswire/ ... (NAMCP) Medical Directors Institute has simultaneously released the ... the NAMCP Medical Diagnostics Dossier Template © , ... dossier template formats for either medical devices or ... unique aspects of each of these technology types ...
(Date:9/16/2014)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... therapies for solid tumor cancers, announced today that its ... as a "Promising Innovative Medicine" (PIM) under the new ... UK in April 2014.  A PIM is the first ... under the EAMS.  The PIM designation ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5
... Sept. 20, 2011 TheraVasc ( www.theravasc.com ) announced the ... drug, TV1001, to diabetic patients. The trial included 12 diabetic ... oral formulations of TV1001, an enteric coated and a non-enteric ... drug.  Based on prior studies conducted in animals, the circulating ...
... American Medical Systems (AMS), a leading provider of world-class ... today announced the launch of a new consumer friendly website ... partners learn how penile prosthetic implants can restore sexual function ... the popularity of ED medications, these drugs fail to resolve ...
Cached Medicine Technology:TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients 2New Website Provides Comprehensive Resource to Anyone With Erectile Dysfunction 2New Website Provides Comprehensive Resource to Anyone With Erectile Dysfunction 3
(Date:9/16/2014)... Francisco, September 15, 2014A prospective study that compared ... patients with bone metastases demonstrates that single fraction ... multiple fraction radiation therapy (MFRT) when pain, function ... research presented today at the American Society for ... study indicates that improvements in patients, pain, function ...
(Date:9/16/2014)... 16, 2014 Fresh shiitake mushrooms ... and potassium. They are second-most consumed mushroom worldwide, ... their healing and health properties. , In addition ... can stimulate and strengthen the immune system and ... polycharrides, including beta glucans . These medicinal ...
(Date:9/16/2014)... 16, 2014 Synergy Research Group has ... gives the best detail and analysis of the state ... a variety of sources, including Ministry of Health in ... will give readers actionable intelligence on clinical trials in ... relied on by the local and international life science ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new blog post ... bad heart condition. , Clients who have a bad ... they compare quotes. Most agencies will insure applicants who ... actual and past medical condition. , If someone ... in the past, his or her chances of finding ...
(Date:9/16/2014)... had children (parous women) appear to have an ... the subtype that carries a higher mortality rate ... ancestry. A similar relationship was found for ... and increased risk of estrogen receptor-negative and triple-negative ... who had never breastfed. These findings, published in ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Synergy Research Group Debuts Ukraine Orange Paper 2Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2
... The Food and Drug Administration (FDA) has awarded ... three-year, $1 million Orphan Products Development grant to ... the skin or internal organs., The unique, interdisciplinary, ... Beth Drolet, M.D., professor of dermatology and pediatrics, ...
... Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center ... possible to sustain therapeutic gene expression in the central ... the presence of an anti-viral immune response mechanism that ... demonstrated in an animal model that the delivery system ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... researchers say , THURSDAY, Oct. 25 (HealthDay News) -- ... can lessen cardiac injuries after heart attack and boost patient ... study in this week,s issue of The Lancet , ... muscle (infarct) and lessened what,s known as "reperfusion injuries," caused ...
... AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Webcast, When: November 1, 2007 @ 8:30 AM ET, ... the Internet -- Simply log on to the web at the ... Lisa Gould of AMICAS, Inc, 617-779-7892. If you are ...
... can search, sort, and compare more than 500 health ... plans on quality ... World Report and the,National Committee for Quality Assurance (NCQA) today ... ranking of U.S. health,maintenance organizations and point-of-service plans. Coinciding with ...
Cached Medicine News:Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: